Long Term Surging Stock: NovaBay Pharmaceuticals (NYSE: NBY)

Biotech stock with a long history but a cheap price, NovaBay Pharmaceuticals (NYSE: NBY) is popping above 27% on over 30 million shares of the daily volume. It is happening due to the massive distribution of antiseptic innovation Avenova by the prominent Amazon and Walmart.

NovaBay is not having a headache on developing the COVID-19 vaccine that could lift its stock significantly. Instead of spending time and resources on extravagant projects the company tries to increase its revenue via simple products and solutions.

Under $1.5 NBY shares still pull many investors by intriguing their strategies with negative EPS and low price. Only gamblers may jump onto this risky investment now.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life